Medical Cannabis on the NHS — What UK Patients Need to Know
In almost all cases you cannot get medical cannabis on the NHS — here is the full picture
Information only: This page provides factual information about NHS policy and does not constitute medical or legal advice. For personal medical decisions, always consult a qualified clinician. LeafMe is an independent price comparison and information service — we are not affiliated with the NHS.
The Reality: NHS vs Private Medical Cannabis
Medical cannabis was legalised in England, Scotland and Wales in November 2018. Yet six years on, the gap between what the law permits and what the NHS delivers remains enormous. Understanding why requires a clear look at the numbers.
- Since legalisation, NHS medical cannabis prescriptions total only a few hundred — almost exclusively for childhood epilepsy (Epidyolex) and MS spasticity (Sativex in limited cases).
- By contrast, the private medical cannabis sector has issued over 200,000 prescriptions to more than 150,000 active patients as of 2024.
- NICE (the National Institute for Health and Care Excellence) has reviewed the evidence and issued guidance that effectively prevents NHS funding for most indications — citing a lack of large-scale randomised controlled trials.
- NHS consultant physicians are technically permitted to prescribe but face significant barriers: no established dosing guidelines, concerns about medicolegal liability, and institutional pressure not to prescribe outside NICE-approved pathways.
- The NHS treats 40+ conditions with cannabis privately but funds essentially none of them on the NHS, creating a significant equity gap between patients who can afford private care and those who cannot.
The Three Exceptions — What the NHS Does Prescribe
Three cannabis-derived medicines have received NICE approval or NHS commissioning support and are prescribable on the NHS under specific, narrow circumstances.
Severe Childhood Epilepsy
Epidyolex (cannabidiol)NICE-approved for children aged 2+ with Dravet syndrome or Lennox-Gastaut syndrome whose seizures are not adequately controlled by other medications. Pure CBD with no THC. Must be prescribed by a specialist paediatric neurologist.
- Licensed for children aged 2 and over
- Available on the NHS since 2019
- CBD only — no intoxicating effects
- Typically used alongside other anticonvulsants
MS-Related Spasticity
Sativex (nabiximols THC:CBD)NICE approved Sativex for adults with MS whose spasticity has not responded adequately to other treatments. Availability varies significantly by NHS region due to local commissioning decisions. Access is restricted even where licensed.
- Oromucosal spray: 2.7mg THC + 2.5mg CBD per spray
- Adults with moderate-to-severe MS spasticity only
- Requires failure of at least two spasticity treatments
- Subject to local commissioning — often unavailable
Chemotherapy-Induced Nausea
Nabilone (synthetic THC)Nabilone is a synthetic cannabinoid (not derived from the cannabis plant) used for nausea and vomiting caused by chemotherapy, where conventional antiemetics have been ineffective. It is a last-resort option in oncology settings.
- Synthetic cannabinoid — not plant-derived cannabis
- Used as a second or third-line antiemetic
- Restricted to chemotherapy patients
- Licensed and available in NHS hospital pharmacies
Why Won’t NHS Doctors Prescribe?
The reluctance of NHS clinicians to prescribe medical cannabis is not simply bureaucratic inertia. It reflects a genuinely complex set of clinical, regulatory and institutional pressures.
Lack of RCT evidence
NICE requires randomised controlled trial data to recommend treatments for NHS funding. Most cannabis evidence comes from observational studies and patient registries. This is partly a chicken-and-egg problem — the Schedule 1 status of cannabis until 2018 made clinical trials extremely difficult to conduct.
Medicolegal liability
NHS consultants are personally responsible for prescriptions outside NICE guidelines under their indemnity arrangements. Without clear dosing protocols and outcome data, many specialists are unwilling to accept the professional risk, regardless of patient demand.
Budget pressures
NHS commissioning bodies (ICBs) must approve funding for treatments. Medical cannabis products are expensive relative to established generics. Without NICE cost-effectiveness endorsement, ICBs rarely agree to fund cannabis treatments at scale.
Specialist shortage
Only consultants on the GMC Specialist Register can prescribe. NHS waiting lists for relevant specialties — neurology, psychiatry, pain medicine — are 12 to 24 months or more in most areas. Even if a specialist wanted to prescribe, patients face very long waits simply to get an appointment.
NHS Referral Pathway — Does It Exist?
Technically, a GP can refer a patient to an NHS specialist who may prescribe medical cannabis. In practice, this pathway is almost never used outside the three approved exceptions.
- Your GP cannot initiate a cannabis prescription themselves — only GMC Specialist Register consultants can do so.
- NHS neurology, psychiatry and pain medicine referral waits average 12–24+ months in England.
- Once referred, a specialist is very unlikely to prescribe cannabis unless you have one of the three NICE-approved conditions.
- There are no NHS cannabis clinics. Patients seeking cannabis for conditions like ADHD, anxiety, chronic pain or sleep disorders will not access it via NHS referral in the current environment.
- The All-Party Parliamentary Group on Medical Cannabis under Prescription has repeatedly called for improved NHS access, but systemic change has been slow.
- Some campaigners, including Volteface and the Cannabis Industry Council, are lobbying for NHS pilot programmes — these may change the picture in future years.
The Private Route — How It Works
For the overwhelming majority of UK patients, the private route is the only realistic way to access medical cannabis. The process is straightforward and typically takes 1–3 weeks from first enquiry to first prescription.
Check your eligibility
Private clinics treat 40+ conditions including chronic pain, ADHD, anxiety, PTSD, insomnia, MS, fibromyalgia and more. You generally need to have tried at least two conventional treatments without adequate success. Bring your medical history and medication records to your consultation.
Choose a licensed clinic
Book with a GMC-registered private medical cannabis clinic. Most offer online video consultations, making them accessible from anywhere in the UK. Compare UK cannabis clinics on LeafMe — including consultation fees, specialties and patient reviews.
Attend your specialist consultation
A consultant (typically a psychiatrist, neurologist or pain specialist) reviews your case. Initial consultations last 30–45 minutes and cost £150–200. If you meet the clinical criteria, a prescription is issued at the same appointment or shortly after.
Prescription dispensed and delivered
Your prescription is sent electronically to a GPhC-registered UK dispensary. Medication is typically delivered in 1–3 working days in discreet, pharmacy-grade packaging. Follow-up appointments (usually monthly) adjust dosing and monitor progress.
Most Affordable Private Options
While NHS access is essentially unavailable for most conditions, these are the most affordable licensed UK medical cannabis products currently available via private prescription — sorted by price per gram.
LGP Capsules 10mg THC
0.0% CBD · 10.0% THC
Curaleaf Sleep Caps 15mg
0.0% CBD · 15.0% THC
Spectrum Blue 5mg Caps
0.0% CBD · 5.0% THC
Releaf Night Capsules
2.0% CBD · 10.0% THC
Aurora CBD15 Capsules
15.0% CBD · 0.0% THC
Tilray Soft Gel 5mg
0.0% CBD · 5.0% THC
NHS vs Private Medical Cannabis — At a Glance
A direct comparison of the two routes for UK patients.
| Factor | NHS | Private |
|---|---|---|
| Availability | Effectively unavailable for most conditions | Widely available for 40+ conditions |
| Wait time | 12–24 months+ (specialist referral) | 1–3 weeks from booking |
| Cost to patient | Free if obtainable — but practically unobtainable | £150–200 consultation + £100–300/month product |
| Conditions treated | Only 3 specific conditions (epilepsy, MS, chemo nausea) | 40+ including ADHD, anxiety, chronic pain, PTSD, insomnia |
| Products available | 3 specific drug products only | 150+ licensed products from multiple manufacturers |
| Prescriber | NHS consultant specialist only (GP cannot prescribe) | Private GMC-registered specialist consultant |
| Legal status | Both routes are fully legal — Schedule 2 licensed products | Both routes are fully legal — Schedule 2 licensed products |
| Insurance coverage | n/a | Rarely covered by private health insurers |
Patients Who Couldn’t Wait for the NHS
The 150,000+ patients now accessing cannabis privately represent a diverse group — many had exhausted NHS options before exploring the private route.
